PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16926300

False-positive Epo test concerns unfounded.

Don Catlin·Gary Green·Michael Sekera·Paul Scott·Borislav Starcevic
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

ErythropoietinFalse Positive ReactionsHumansReagent Kits, DiagnosticRecombinant ProteinsReproducibility of ResultsCommentLetter

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Don Catlin, Gary Green, Michael Sekera, Paul Scott, Borislav Starcevic. 2006-09-01. False-positive Epo test concerns unfounded.. https://doi.org/10.1182/blood-2006-03-006890

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safety considerations for erythropoietin treatment in patients with cancer.

Cancer-related anaemia, which affects many patients with cancer, can effectively be treated by erythropoietic proteins. Erythropoietic proteins increase haemoglobin levels, reduce the risk for transfusions and also improve the quality of life of patients. When used according to published practice guidelines, these proteins benefit many patients and are generally well tolerated. Important side effects are hypertension and thromboembolic events, either of which occurs in < 10% of the patients. Administration only in anaemic patients, avoidance of target haemoglobin levels > 130 g/l, proper dose adjustments and close monitoring during treatment will ensure the clinical safety of these proteins. However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study.

Erythropoietin↗